A Physiologically Based Pharmacokinetic (PBPK) Model to Describe Organ Distribution of Ga-DOTATATE in Patients Without Neuroendocrine Tumors

Overview

Journal EJNMMI Res

Date 2021 Aug 16

PMID 34398356

Citations 7

Authors

H Siebinga

B J de Wit-van der Veen

J H Beijnen

M P M Stokkel

T P C Dorlo

A D R Huitema

J J M A Hendrikx

Affiliations

Soon will be listed here.

Abstract

Background: Physiologically based pharmacokinetic (PBPK) models combine drug-specific information with prior knowledge on the physiology and biology at the organism level. Whole-body PBPK models contain an explicit representation of the organs and tissue and are a tool to predict pharmacokinetic behavior of drugs. The aim of this study was to develop a PBPK model to describe organ distribution of Ga-DOTATATE in a population of patients without detectable neuroendocrine tumors (NETs).

Methods: Clinical Ga-DOTATATE PET/CT data from 41 patients without any detectable somatostatin receptor (SSTR) overexpressing tumors were included. Scans were performed at 45 min (range 30-60 min) after intravenous bolus injection of Ga-DOTATATE. Organ (spleen, liver, thyroid) and blood activity levels were derived from PET scans, and corresponding DOTATATE concentrations were calculated. A whole-body PBPK model was developed, including an internalization reaction, receptor recycling, enzymatic reaction for intracellular degradation and renal clearance. SSTR2 expression was added for several organs. Input parameters were fixed or estimated using a built-in Monte Carlo algorithm for parameter identification.

Results: Ga-DOTATATE was administered with a median peptide amount of 12.3 µg (range 8.05-16.9 µg) labeled with 92.7 MBq (range 43.4-129.9 MBq). SSTR2 amounts for spleen, liver and thyroid were estimated at 4.40, 7.80 and 0.0108 nmol, respectively. Variability in observed organ concentrations was best described by variability in SSTR2 expression and differences in administered peptide amounts.

Conclusions: To conclude, biodistribution of Ga-DOTATATE was described with a whole-body PBPK model, where tissue distribution was mainly determined by variability in SSTR2 organ expression and differences in administered peptide amounts.

Citing Articles

Personalized metronomic radiopharmaceutical therapy through injection profile optimization via physiologically based pharmacokinetic (PBPK) modeling.

Golzaryan A, Soltani M, Moradi Kashkooli F, Saboury B, Rahmim A Sci Rep. 2025; 15(1):4052.

PMID: 39901004 PMC: 11791192. DOI: 10.1038/s41598-025-86159-9.

Physiologically based radiopharmacokinetic (PBRPK) modeling to simulate and analyze radiopharmaceutical therapies: studies of non-linearities, multi-bolus injections, and albumin binding.

Fele-Paranj A, Saboury B, Uribe C, Rahmim A EJNMMI Radiopharm Chem. 2024; 9(1):6.

PMID: 38252191 PMC: 10803696. DOI: 10.1186/s41181-023-00236-w.

Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [Lu]Lu-DOTA-TATE therapy.

Gubbi S, Al-Jundi M, Auh S, Jha A, Zou J, Shamis I Front Endocrinol (Lausanne). 2023; 14:1275813.

PMID: 37886645 PMC: 10598842. DOI: 10.3389/fendo.2023.1275813.

Predicting [Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling.

Siebinga H, de Wit-van der Veen B, Beijnen J, Stokkel M, Dorlo T, Huitema A EJNMMI Phys. 2023; 10(1):48.

PMID: 37615812 PMC: 10449733. DOI: 10.1186/s40658-023-00565-4.

Predicting the effect of different folate doses on [Ga]Ga-PSMA-11 organ and tumor uptake using physiologically based pharmacokinetic modeling.

Siebinga H, Hendrikx J, Huitema A, de Wit-van der Veen B EJNMMI Res. 2023; 13(1):60.

PMID: 37318681 PMC: 10272068. DOI: 10.1186/s13550-023-01008-y.

References

Reubi J, Schar J, Waser B, Wenger S, Heppeler A, Schmitt J . Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000; 27(3):273-82. DOI: 10.1007/s002590050034. View

Sabet A, Nagarajah J, Dogan A, Biersack H, Sabet A, Guhlke S . Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic.... EJNMMI Res. 2013; 3(1):82. PMC: 3877953. DOI: 10.1186/2191-219X-3-82. View

Gospavic R, Knoll P, Mirzaei S, Popov V . Physiologically Based Pharmacokinetic (PBPK) Model for Biodistribution of Radiolabeled Peptides in Patients with Neuroendocrine Tumours. Asia Ocean J Nucl Med Biol. 2016; 4(2):90-7. PMC: 4938879. DOI: 10.7508/aojnmb.2016.02.005. View

Sandstrom M, Velikyan I, Garske-Roman U, Sorensen J, Eriksson B, Granberg D . Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med. 2013; 54(10):1755-9. DOI: 10.2967/jnumed.113.120600. View

Hardiansyah D, Attarwala A, Kletting P, Mottaghy F, Glatting G . Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic model. Phys Med. 2017; 42:298-304. DOI: 10.1016/j.ejmp.2017.06.024. View

Kaemmerer D, Peter L, Lupp A, Schulz S, Sanger J, Prasad V . Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011; 38(9):1659-68. DOI: 10.1007/s00259-011-1846-5. View

Mittra E . Neuroendocrine Tumor Therapy: Lu-DOTATATE. AJR Am J Roentgenol. 2018; 211(2):278-285. DOI: 10.2214/AJR.18.19953. View

Kletting P, Thieme A, Eberhardt N, Rinscheid A, DAlessandria C, Allmann J . Modeling and Predicting Tumor Response in Radioligand Therapy. J Nucl Med. 2018; 60(1):65-70. DOI: 10.2967/jnumed.118.210377. View

Pauwels E, Cleeren F, Bormans G, Deroose C . Somatostatin receptor PET ligands - the next generation for clinical practice. Am J Nucl Med Mol Imaging. 2018; 8(5):311-331. PMC: 6261874. View

10.

Walker R, Smith G, Liu E, Moore B, Clanton J, Stabin M . Measured human dosimetry of 68Ga-DOTATATE. J Nucl Med. 2013; 54(6):855-60. PMC: 4472480. DOI: 10.2967/jnumed.112.114165. View

11.

Pilari S, Gaub T, Block M, Gorlitz L . Development of Physiologically Based Organ Models to Evaluate the Pharmacokinetics of Drugs in the Testes and the Thyroid Gland. CPT Pharmacometrics Syst Pharmacol. 2017; 6(8):532-542. PMC: 5572381. DOI: 10.1002/psp4.12205. View

12.

Chakravarty R, Chakraborty S, Ram R, Vatsa R, Bhusari P, Shukla J . Detailed evaluation of different (68)Ge/(68)Ga generators: an attempt toward achieving efficient (68)Ga radiopharmacy. J Labelled Comp Radiopharm. 2016; 59(3):87-94. DOI: 10.1002/jlcr.3371. View

13.

Xia Y, Zeng C, Zhao Y, Zhang X, Li Z, Chen Y . Comparative evaluation of Ga-labelled TATEs: the impact of chelators on imaging. EJNMMI Res. 2020; 10(1):36. PMC: 7158967. DOI: 10.1186/s13550-020-00620-6. View

14.

Schottelius M, Simecek J, Hoffmann F, Willibald M, Schwaiger M, Wester H . Twins in spirit - episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE. EJNMMI Res. 2015; 5:22. PMC: 4402678. DOI: 10.1186/s13550-015-0099-x. View

15.

Sadowski S, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P . Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol. 2015; 34(6):588-96. PMC: 4872030. DOI: 10.1200/JCO.2015.64.0987. View

16.

Kletting P, Muller B, Erentok B, Schmaljohann J, Behrendt F, Reske S . Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy. Med Phys. 2012; 39(9):5708-17. DOI: 10.1118/1.4747266. View

17.

Ferl G, Dumont R, Hildebrandt I, Armijo A, Haubner R, Reischl G . Derivation of a compartmental model for quantifying 64Cu-DOTA-RGD kinetics in tumor-bearing mice. J Nucl Med. 2009; 50(2):250-8. PMC: 3319446. DOI: 10.2967/jnumed.108.054049. View

18.

Begum N, Thieme A, Eberhardt N, Tauber R, DAlessandria C, Beer A . The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for Lu-Labeled PSMA Peptides. J Nucl Med. 2018; 59(6):929-933. DOI: 10.2967/jnumed.117.203505. View

19.

Hennrich U, Kopka K . Lutathera: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals (Basel). 2019; 12(3). PMC: 6789871. DOI: 10.3390/ph12030114. View

20.

Waser B, Tamma M, Cescato R, Maecke H, Reubi J . Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med. 2009; 50(6):936-41. DOI: 10.2967/jnumed.108.061457. View